Zusammenfassung
Diabetes mellitus gehört zu den weltweit am stärksten zunehmenden Erkrankungen, wobei ca. 90–95% der Patienten an Diabetes Typ 2 erkranken. Diabetes Typ 2 wird durch eine periphere Insulinresistenz und einen zunehmenden Verlust der β-Zell-Funktion charakterisiert. Angesichts der Komplikationen insbesondere im Bereich kardiovaskulärer Erkrankungen ist eine zuverlässige antihyperglykämische Therapie unabdingbar. In diesem Beitrag werden die zugrunde liegenden pathophysiologischen Mechanismen von Diabetes Typ 2 kurz dargestellt und die aktuellen oralen Antidiabetika erläutert.
Abstract
Diabetes mellitus belongs to the most rapidly increasing diseases worldwide. Approximately 90–95% of these patients suffer from type 2 diabetes which is characterized by peripheral insulin resistance and an increasing loss of β-cell function. In view of the manifold complications of diabetes concerning mainly the cardiovascular system, a reliable antihyperglycemic therapy is indispensable. This report briefly depicts the underlying pathophysiological mechanisms and describes the currently available oral antidiabetic drugs.
Literatur
Brooks-Worrell B, Narla R, Palmer JP (2012) Biomarkers and immune-modulating therapies for type 2 diabetes. Trends Immunol 33:546–553
Burant CF, Viswanathan P, Marcinak J et al (2012) TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomized, double-blind, placebo-controlled trial. Lancet 379:1403–1411
Chan NN, Brain HP, Feher MD (1998) Metformin-associated lactic acidosis: a rare or very rare clinical entity? Diabetes Care 21:1659–1663
Dormandy JA, Charbonnel B, Eckland DJ et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:1279–1289
European Medicine Agency (2012) European medicines agency recommends authorisation of novel treatment for type 2 diabetes. EMA/CHMP/257385/2012
Inzucchi SE, Bergenstal RM, Buse JB et al (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55:1577–1596
Larsen CM, Faulenbach M, Vaag A et al (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356:1517–1526
Matthaei S, Bierwirth R, Fritsche A et al (2009) Medikamentöse antihyperglykämische Therapie des Diabetes mellitus Typ 2– Update der Evidenzbasierten Leitlinie der Deutschen Diabetes-Gesellschaft. Diabetologie 4:32–64
Nissen SE, Wolski K (2010) Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 170:1191–1201
Nolan CJ, Damm P, Prentki M (2011) Type 2 diabetes across the generations: from pathophysiology to prevention and management. Lancet 378:169–181
Bundesinstitut für Arzneimittel und Medizinprodukte (Hrsg) (2012) Risikoinformation BfArm; Pioglitazon (Actos®, Competact®, Tandemact®): Leitfaden für die Verordnung und das Risikomanagement
Tahrani AA, Bailey CJ, Del Prato S, Barnett AH (2011) Management of type 2 diabetes: new and future developments in treatment. Lancet 378:182–197
Thornbury NA, Gallwitz B (2009) Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Pract Res Clin Endocrinol Metab 23:479–486
UK prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type-2 diabetes (UKPDS 33). Lancet 352:837–853
UKPDS Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352:854–865
DeFronzo RA (2009) Banting lecture. From the triumvirate to the ominious octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58:773–795
Interessenkonflikt
Die korrespondierende Autorin gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Oetjen, E. Orale Antidiabetika. Kardiologe 6, 467–473 (2012). https://doi.org/10.1007/s12181-012-0457-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12181-012-0457-0